SCHEMBL2362399

SCHEMBL2362399

CCCc1ccc(C(=O)CC(=O)c2ccc(C(=O)OC)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4A11 Q02928 2/20 0.60
CYP4F2 P78329 1/20 0.58
LOXL2 Q9Y4K0 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MAPT P10636 3/20 0.55
MEN1 O00255 1/20 0.55
NPC1 O15118 1/20 0.55
RAB9A P51151 1/20 0.55
KMT2A Q03164 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
PLK1 P53350 1/20 0.54
ALDH1A1 P00352 2/20 0.50
TP53 P04637 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
ALOX12 P18054 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1807631 0.93 CYP4A11 (0.68) CYP4A11CYP4F2LOXL2L3MBTL1MAPT
Ammonia Solution, Strong SCHEMBL9650075 0.91 CYP4A11 (0.66) CYP4A11CYP4F2LOXL2L3MBTL1MAPT
SCHEMBL2354104 0.90 CYP4A11 (0.66) CYP4A11CYP4F2LOXL2MAPTMEN1
SCHEMBL7631396 0.89 L3MBTL1 (0.67) L3MBTL1MAPTMEN1NPC1RAB9A
SCHEMBL2353177 0.89 CYP4A11 (0.67) CYP4A11CYP4F2LOXL2MAPTMEN1
SCHEMBL2363313 0.87 HAO1 (0.67) CYP4A11CYP4F2MAPTMEN1KMT2A
SCHEMBL2352655 0.87 HAO1 (0.67) CYP4A11CYP4F2MAPTMEN1KMT2A
SCHEMBL11391147 0.85 CA1 (0.64) CYP4A11CYP4F2LOXL2MAPTMEN1
SCHEMBL21656469 0.85 CYP4A11 (0.58) CYP4A11CYP4F2LOXL2MAPTMEN1
SCHEMBL15580575 0.85 NPC1 (0.59) L3MBTL1NPC1RAB9AKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921309-B2 Lipopeptide compounds and their use UNIQUEST PTY LIMITED (AU) 2014-12-30 US disclosed
EP-2350119-B1 LIPOPEPTIDE COMPOUNDS AND THEIR USE UNIQUEST PTY LTD (AU) 2014-10-29 EP disclosed
US-20110224129-A1 Lipopeptide Compounds and Their Use MERLION PHARMACEUTICALS PTE LTD (SG) 2011-09-15 US disclosed
EP-2350119-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE Merlion Pharmaceuticals Pte Ltd. (SG) 2011-08-03 EP disclosed
WO-2010062264-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE MERLION PHARMACEUTICALS PTE LTD (SG) 2010-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224129-A1 Lipopeptide Compounds and Their Use VIP, LTA, CLPTM1 CYP4A11 3797/4885CYP4F2 4600/4885LOXL2 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.